FDA approved new type II diabetes drug

By ASN Staff

The new drug, developed by Merck & Co and Pfizer Inc., is an oral drug known generically as ertugliflozin and in the class of SGLT2 inhibitors, which work to expel excess glucose through urine. The brand name is Steglatro and it will compete in the market with AstraZeneca Plc's Farxiga, Johnson & Johnson's Invokana, and Eli Lilly and Boehringer Ingelheim's Jardiance.

The US Food and Drug Administration (FDA) approved the drug on December 20, 2017. The drug is expected to be available for sale in early 2018.

Diabetes “affects roughly 30 million Americans and can lead to severe damage to a range of organs, including the eyes and kidneys and significantly increases the risk of heart attack and stoke.”

For the full report, see Reuters.

Category:
Subcategory:
Author:
ASN Staff
Article Image:
Body:

The new drug, developed by Merck & Co and Pfizer Inc., is an oral drug known generically as ertugliflozin and in the class of SGLT2 inhibitors, which work to expel excess glucose through urine. The brand name is Steglatro and it will compete in the market with AstraZeneca Plc's Farxiga, Johnson & Johnson's Invokana, and Eli Lilly and Boehringer Ingelheim's Jardiance.

The US Food and Drug Administration (FDA) approved the drug on December 20, 2017. The drug is expected to be available for sale in early 2018.

Diabetes “affects roughly 30 million Americans and can lead to severe damage to a range of organs, including the eyes and kidneys and significantly increases the risk of heart attack and stoke.”

For the full report, see Reuters.

Area(s) of Interest:
Date:
Friday, December 22, 2017